Pharmaceutical and healthcare report offering, “Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market.
Online PR News – 22-May-2010 – – Pharmaceutical and healthcare report offering, “Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.
The scope of the report includes:
Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global pneumonia market landscape? - Identify, understand and capitalize.
Forest Laboratories, Inc
Advanced Life Sciences
For more information on the report, kindly visit :